Navigation Links
Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology

NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed the publication of an article in the Journal of of Cardiology (JACC) reviewing the TAXUS ATLAS clinical trial, which evaluates the Company's second-generation TAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. The article in the April 24 edition of JACC concluded that the shorter procedure time and lower bailout rate of the TAXUS Liberte Stent system compared to the TAXUS(R) Express2(TM) Stent system may represent a clinical surrogate for the improved deliverability and conformability of the TAXUS Liberte Stent as compared to the TAXUS Express Stent.

TAXUS ATLAS is a global, multi-center single arm trial comparing the TAXUS Liberte paclitaxel-eluting stent system to a case-matched control group of patients from the TAXUS IV and TAXUS V de novo studies that received the TAXUS Express2 paclitaxel-eluting stent system. Even with more complex lesion characteristics(2) compared to the control group, the TAXUS ATLAS trial met its primary endpoint of nine-month target vessel revascularization (TVR) non-inferiority.

The TAXUS ATLAS nine-month results also support safety, as demonstrated by low rates of Major Adverse Cardiac Events (MACE) and stent thrombosis. The MACE rate and its components, including cardiac death, myocardial infarction and TVR, were comparable to control despite the higher percentage of complex lesions for the TAXUS Liberte Stent arm. Cardiac death for the control group was 0.9 percent compared to 0.8 percent for the TAXUS Liberte Stent (p=1.00). Myocardial infarction was 3.9 percent for the control group compared to 3.7 percent for the TAXUS Liberte Stent (p=0.9030). The nine-month TVR rate for the control group was 7.1 percent compared to 8.0 percent for the TAXUS Liberte Stent (p=0.4787). Similar TVR rates of 9.2 percent for the TAXUS Liberte Stent group, as compared to 8.9 perc
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

Post Your Comments:
(Date:11/20/2009)...wswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin... known as DOR BioPharma, Inc., a late-stage biotec...d a consortium to develop thermostable technology ...ines. Soligenix received a $9.4 million grant from...Diseases (NIAID), a division of the National Insti...
(Date:11/19/2009)...ewswire-FirstCall/ -- BioCryst Pharmaceuticals, In... a public offering of 5,000,000 shares of its comm...oceeds of $48.75 million. All of the shares are b...shelf registration statement previously filed with... has also granted the underwriters a 30-day option...
(Date:11/19/2009)...wswire-FirstCall/ -- In a series of new initiative...oration (Nasdaq: HSKA ) ("Heska" or the "Company"...ed website. The upgraded site is the result of se...o align the site with the company,s new brand imag.../www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO )...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3Accumetrics VerifyNow 28R 29 P2Y12 Test Provides Physicians With Information to Assess a Patients Response to Newly Approved Prasugrel 28Effient 28R 51616 1Accumetrics VerifyNow 28R 29 P2Y12 Test Provides Physicians With Information to Assess a Patients Response to Newly Approved Prasugrel 28Effient 28R 51616 2Get the Most Out of Your Run 51614 1Get the Most Out of Your Run 51614 2Get the Most Out of Your Run 51614 3Increase in Thyroid Cancer Puzzles Experts 51611 1Increase in Thyroid Cancer Puzzles Experts 51611 2
(Date:11/21/2009)..., , "This bill provides for an unprecede...is health care about if it is not for preserving a...ed, it must be defeated." Charmaine Yoest ,,...ericans United for Life Action President and CEO D...the Senate by releasing the following statement: ...
(Date:11/21/2009)..., , LONDON, November 21, 2009 /PRNewswire-...est Test Test Test Test Test Test Test Test Test T...est Test Test Test Test Test Test,Test Test Test T... More test More test More test More test More ...test More test More test More test More test More,...
(Date:11/21/2009)... Eric J. Hall, president an...ation of America (AFA) issued the following statem...t detection as part of the new annual wellness for...ction and Affordable Care Act" that was intro...ork, NY (PRWEB) November 21, 2009 -- Eric J. Hall,...
(Date:11/20/2009)..., , PRINCETON, NJ, Nov. 20 /PRNewswire-First...day that a Special Meeting of Shareholders will be... the Meeting is to consider approval of two specia...approve and authorize the sale of all or substanti...n the terms provided for in the asset purchase agr...
(Date:11/20/2009)... Senators and Congressmen i...ble Over their Health Care Vote , ...-- Senators and congressmen running for re-electio...olitical guru Charlie Cook, may come to regret vot...care bill, according to a breaking Zogby Internati...
Breaking Medicine News(10 mins):Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3
...son Introduces Docuscan Patient History System Wit...logy, BLOOMINGTON, Minn., Sept. 4 Today Pearson ...new innovative solution for,digitally capturing pa...Paros(TM) technology enables,digital capture of pa...
...IGH, N.C., Sept. 4 MedThink Communications, an,in...elations, has been,retained by NanoBio Corporation...zed particles to eradicate skin infections, withou...nd medical,communications in order to advance Nano...
...he next battle in the war on asthma symptom contro... , It turns out that Mom and Dads leeriness towar...king theyre not essential, or believing they pose ...e-breathing disease do not take their prescription...
...he Healthy Steps for Young Children Program, which...ric practices, continued to benefit families more ...ding to a study by researchers from the Johns Hopk...ir childs health care, greater odds that parents w...
...isition of Consultech Strengthens Omnicom,s Presen...althcare Market, BEIJING, Sept. 3 Omnicom Group ... advertising and marketing,services group, has acq...nd marketing communications company based in,China...
... In this weeks press release: , , Renal functio...-induced acute lung injury in mice by mesenchymal ...ease mention PLoS Medicine in your report and use ...ction and coronary heart disease , , John Danesh ...
Other Medicine News:Health News:New 'Smart' Technology Makes Patient Data Collection Easier, More Efficient 2Health News:MedThink Communications Retained by NanoBio Corporation 2Health News:Parents' perceptions can hamper kids' asthma care, study finds 2Health News:Parents' perceptions can hamper kids' asthma care, study finds 3Health News:Practice-based intervention has sustained benefits for children and families 2Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 2Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 3Health News:Renal function and heart disease, and more 2
Universal Facial Wrap
Facial Mask
Abdominal Binders - 9" & 12"
Abdominal Girdle V-840
Medicine Products: